| Display title | Chemistry:Mavatrep |
| Default sort key | Mavatrep |
| Page length (in bytes) | 4,501 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 948911 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>WikiG |
| Date of page creation | 00:05, 6 February 2024 |
| Latest editor | imported>WikiG |
| Date of latest edit | 00:05, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist. It is an investigational analgesic that may be a potential treatment for analgesia and/or inflammation.
Phase I trials have been completed in healthy Japanese and Caucasian volunteers.
Potential common adverse effects include... |
